Additional funding will allow the MHRA and NICE to continue developing clear, proportionate guidance for digital mental health technologies, supporting safer, more effective tools for people across the UK.
Similar Posts
MHRA statement on the PATHWAYS puberty blocker trial
With all complex clinical trials, MHRA’s top priority is the safety and wellbeing of the trial participants
Guidance: CLOSED AI Airlock Phase 2 application
The call for applications for phase 2 of the AI Airlock is now closed.
Class 2 Medicines Recall: Depo-Medrone 80 mg in 2 mL, Maxearn Limited EL(25)A/29
A batch of Depo-Medrone has been released to the market with an error. The vial over label incorrectly states that the total vial content is 40 mg in 1 mL, when the correct total vial content is 80mg in 2 mL (with a concentration of 40mg/ml of methylprednisolone acetate).
MHRA calls on public to report side effects and suspected fakes during #MedSafetyWeek
The tenth annual #MedSafetyWeek brings together more than 130 medicines regulators and health organisations across 117 countries to encourage people to report suspected side effects from medicines and device incidents.
MHRA seeks input on AI regulation at ‘pivotal moment’ for healthcare
National Commission is seeking evidence to shape regulation of AI in healthcare and support the UK’s ambition for a world-leading, AI-enabled NHS
Chris Kessler: How access to innovative rare therapies can transform the lives of children like Charlie
A story of hope, medical innovation, and the impact of effective regulation on access to treatment.